OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
A new standard of care for advanced-stage urothelial carcinoma	1000
Tasadenoturev active in DIPG	1000
From little subclones grow mighty oaks	783
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	771
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	718
Ecological management of the microbiota in patients with cancer	713
Novel ICI–TKI combination improves HCC outcomes	709
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	609
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	606
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	576
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	551
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	507
Hodgkin lymphoma: great progress with room for improvement	486
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	460
Current understanding and management of CAR T cell-associated toxicities	427
Gut microbiota in colorectal cancer development and therapy	422
Contrasting results with second-line CAR T cells in large B cell lymphoma	416
Sacituzumab tirumotecan improves OS in mTNBC	391
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	384
Ponatinib superior to imatinib in Ph+ ALL	382
Mortality is similar with active monitoring	378
From ESMO 2022	376
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	365
Belzutifan as a new option in pheochromocytomas and paragangliomas	338
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	288

Understanding and overcoming multidrug resistance in cancer	285
Harnessing cytokines and chemokines for cancer therapy	283
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	283
Humanized mouse models for immuno-oncology research	279
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	277
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	277
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	275
Survival benefit with second-line combination in endometrial cancer	272
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	270
Craniospinal irradiation improves leptomeningeal metastasis control	269
Improving outcomes in patients with oesophageal cancer	262
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	261
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	261
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	246
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	239
Biomarkers for immunotherapy of hepatocellular carcinoma	239
Harnessing big data to characterize immune-related adverse events	238
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	206
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	204
Spatial landscapes of cancers: insights and opportunities	195
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	195
New CAPSTONE of SCLC therapy?	193
SHINE a light: frontline ibrutinib for MCL	191
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	185
Women with clinically node negative breast cancer can safely avoid axillary surgery	172
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	171
From ESMO 2023: advances in lung cancer	170
Prospective comparisons support the use of navigational bronchoscopy	155
DREAMseq of therapy for BRAF-mutant melanoma	155
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	144
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	143
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	141
Mitigating acute chemotherapy-associated adverse events in patients with cancer	137
Targeting chromosomal instability in patients with cancer	135
Circulating tumour DNA — looking beyond the blood	134
Response to neoadjuvant endocrine therapy complements recurrence score	125
Long-term outcomes following CAR T cell therapy: what we know so far	125
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	121
Multiomics STEP up in correlative analysis of response to CAR T cells	120
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	120
From the ESMO Congress 2023	119
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	118
Sentinel lymph node biopsy improves surgical management of cervical cancer	117
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	107
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	104
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	103
HAIC-FO improves outcomes in HCC	101
Newly approved cancer drugs in China — innovation and clinical benefit	100
Lung cancer in patients who have never smoked — an emerging disease	99
Claudin 18.2 as a novel therapeutic target	97

Clinical implications of T cell exhaustion for cancer immunotherapy	97
Combining CAR T cells effective in RRMM	95
Enhancing immunotherapy with tumour-responsive nanomaterials	95
Targeted biopsy reduces detection of clinically insignificant cancer	94
T-DXd effective as second-line therapy in G/GEJ cancers	93
Second-line tarlatamab improves OS in SCLC	90
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer	89
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	86
Less-frequent surveillance is noninferior to annual mammography	86
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	81
Barriers in access to oncology drugs — a global crisis	79
Translating biological insights into improved management of endometrial cancer	78
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	75
Two decades of advances in clinical oncology — lessons learned and future directions	75
BrECADD raises the bar in classical Hodgkin lymphoma	74
HSCT prolongs remission of high-risk CTCLs	73
Nirogacestat effective in desmoid tumours	73
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	71
Thermal ablation is safer than resection of colorectal liver lesions	70
Cured but breathless: the growing burden of DIILD in cancer survivors	69
Promising OS with oncolytic virotherapy	68
GPRC5D-CAR T cells active in MM	66
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	66
Promise with co-administration of CAR T cells	65
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	65
Non-financial conflicts of interest	63
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	58
Efficacy of TILs confirmed	56
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	51
Exploiting bacteria for cancer immunotherapy	49
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	49
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	48
Neoadjuvant pembrolizumab improves outcomes	47
The current state of the art and future trends in RAS-targeted cancer therapies	47
Repotrectinib effective in ROS1-fusion-positive NSCLC	46
KN046 shows tolerability and activity in TNBC	45
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	45
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	44
Problematic crossovers in cancer drug trials	42
LAG3 inhibition improves outcomes	40
Integrated MRI-guided radiotherapy — opportunities and challenges	39
The emerging roles of γδ T cells in cancer immunotherapy	38
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	38
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	35
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	35
National value-based pricing negotiation for oncology drugs — lessons from China	34
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	31
CAR T cells induce durable remission of neuroblastoma	27
GPRC5D as a novel immunotherapeutic target in multiple myeloma	27
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	26
Personalizing adjuvant therapy for patients with colorectal cancer	25
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	25
Epcoritamab is active in large B cell lymphomas	23
Laparoscopic TME is non-inferior	23
PERSEUS triumphs — efficacy of daratumumab confirmed in transplant-eligible NDMM	22